MarketPeel
Insider Trading Intelligence
AP

Amy Parison

EDIT
SVP, CHIEF FINANCIAL OFFICER · EDITAS MEDICINE, INC. · CIK 0002063082
FILING MIX · LIFETIME25%/75%
BUYS
2
SELLS
6
TOTAL VALUE
$6.9K
COMPANIES
1
ACTIVE SINCE
Apr 2025
HOLDINGS NOW
14,970
AVG SELL PX
$2.32
TRADE KIND
SHOWING 8 / 8
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Amy Parison, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+0.00%+15.20%+0.91%+14.29%+14.21%
14d5+0.00%+11.36%-0.01%+11.38%+9.12%
30d5+20.00%+25.28%+1.51%+23.78%+34.48%
60d5+20.00%+27.25%+4.86%+22.39%+29.77%
90d5+40.00%+17.52%+4.98%-0.48%-4.37%
180d5(1 pending)+50.00%+8.84%+9.94%-13.58%-20.62%
1y5(4 pending)+0.00%+54.95%
2y5(5 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
EDIT · 14,970 shares · as of Jun 3, 2026
073,214146,428219,642292,8562026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2025
2025
2025
2026
2026
FLOW · 2 buys / 6 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
464$2.70$1.3K14,970Jun 3, 2026Jun 5, 2026View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
292,856292,856Mar 12, 2026Mar 16, 2026View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
474$2.02$95715,434Mar 3, 2026Mar 4, 2026View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
461$2.15$99315,908Dec 3, 2025Dec 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
458$2.60$1.2K16,369Sep 3, 2025Sep 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
679$2.58$1.8K16,827Aug 7, 2025Aug 8, 2025View →
EDIT
EDITAS MEDICINE, INC.
SALE10b5-1
10b5-1 plan
446$1.72$76917,506Jun 3, 2025Jun 4, 2025View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
34,67234,672Apr 8, 2025Apr 8, 2025View →
Other insiders · EDIT
Loading peer insiders…
About this filer
CIK 0002063082
ROLE
SVP, Chief Financial Officer
PRIMARY
EDIT
COMPANIES
1
ACTIVE SINCE
Apr 2025
MARKETPEEL · /INSIDER/0002063082DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback